MARKET

CRIS

CRIS

Curis
NASDAQ
6.12
-0.37
-5.70%
Opening 12:11 07/22 EDT
OPEN
6.49
PREV CLOSE
6.49
HIGH
6.64
LOW
6.08
VOLUME
24.18K
TURNOVER
0
52 WEEK HIGH
17.49
52 WEEK LOW
3.800
MARKET CAP
36.07M
P/E (TTM)
-0.7047
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CRIS last week (0715-0719)?
Weekly Report · 5h ago
Weekly Report: what happened at CRIS last week (0708-0712)?
Weekly Report · 07/15 12:00
Weekly Report: what happened at CRIS last week (0701-0705)?
Weekly Report · 07/08 12:02
Will Curis' TakeAim Trials Hit The Mark?
NASDAQ · 07/08 09:16
Weekly Report: what happened at CRIS last week (0624-0628)?
Weekly Report · 07/01 12:03
Weekly Report: what happened at CRIS last week (0617-0621)?
Weekly Report · 06/24 12:13
Weekly Report: what happened at CRIS last week (0610-0614)?
Weekly Report · 06/17 12:01
12 Health Care Stocks Moving In Monday's Intraday Session
Seres Therapeutics stock moved upwards by 34.0% to $0.82 during Monday's regular session. Renovaro (NASDAQ:RENB) shares increased by 32.51%. Champions Oncology stock increased by 22.82%. Novavax stock decreased by 14.62%.
Benzinga · 06/10 16:31
More
About CRIS
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.

Webull offers Curis Inc stock information, including NASDAQ: CRIS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CRIS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CRIS stock methods without spending real money on the virtual paper trading platform.